Tyrosine kinase inhibitorFDA-approvedFirst-line
BRAF V600E Inhibitor (Encorafenib)
Generic name: encorafenib
How it works
Blocks the BRAF V600E mutation in cancer cells, which is a genetic abnormality that drives cancer growth.
Cancer types
Melanoma— BRAF V600E-positive
Efficacy
Studies show that around 50% of patients achieved an objective response, with a median overall survival of approximately 14.9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study of Combination Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| New Treatment Option for Chinese Patients with Aggressive Colorectal Cancer | Colorectal Cancer | phase-2 | The Doublet arm demonstrated superior progression-free survival of 4.2 months vs. 2.5 months in the Control arm. | Source → |
| Study of Encorafenib and Binimetinib for BRAF Mutant Melanoma with Brain Metastasis | Melanoma | phase-2 | Treatment with encorafenib plus binimetinib demonstrated a brain metastasis response rate of over 60%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.